10-Q - Voyager Acquisition Corp./Cayman Islands (0002006815) (Filer)

SCHEDULE 13G/A - Voyager Acquisition Corp./Cayman Islands (0002006815) (Subject)

SCHEDULE 13G/A - Voyager Acquisition Corp./Cayman Islands (0002006815) (Subject)

RW - Voyager Acquisition Corp./Cayman Islands (0002006815) (Filer)

425 - Voyager Acquisition Corp./Cayman Islands (0002006815) (Subject)

F-4 - Voyager Acquisition Corp./Cayman Islands (0002006815) (Filer)

8-K - Voyager Acquisition Corp./Cayman Islands (0002006815) (Filer)

425 - Voyager Acquisition Corp./Cayman Islands (0002006815) (Subject)

SCHEDULE 13G/A - Voyager Acquisition Corp./Cayman Islands (0002006815) (Subject)

10-Q - Voyager Acquisition Corp./Cayman Islands (0002006815) (Filer)

ZURICH, SWITZERLAND, July 17, 2025 -- VERAXA Biotech AG ("VERAXA" or the "Company"), an emerging leader in designing novel cancer therapies, and Voyager Acquisition Corp.,  a Cayman Islands exempted company and special purpose acquisition company targeting the healthcare sector (NASDAQ:VACH, "Voyager" or the "SPAC")), announced today the filing of a registration statement on Form F-4 (the "Registration Statement"), which includes a preliminary proxy statement, with the U.S. Securities and Exchange Commission ("SEC") in regards to the proposed Business Combination Agreement announced April 23, 2025. "We are excited to share this pivotal milestone in VERAXA's journey toward becoming a publi

ZURICH, SWITZERLAND, May 29, 2025 -- VERAXA Biotech AG ("VERAXA"), an emerging leader in designing novel cancer therapies and proposed de-SPAC acquisition target of Voyager Acquisition Corp. (NASDAQ:VACH, "Voyager")), announced today it will be attending the upcoming ASCO Annual Meeting and BIO International Convention. At the conferences, Christoph Antz, CEO, and additional members of the VERAXA leadership team will be meeting with potential partners and investors, showcasing the Company's novel Bi-targeted Tumor-Associated Cytotoxicity (BiTAC) platform, and sharing the Company's growth plans as it prepares to list on the NASDAQ later this year. VERAXA is leveraging its proprietary BiTAC p

VERAXA Biotech AG ("VERAXA"), an emerging leader in designing novel cancer therapies and proposed de-SPAC acquisition target of Voyager Acquisition Corp. (NASDAQ:VACH, "Voyager")), announced today the appointment of Rick Austin, Ph.D. as Chief Scientific Officer, effective May 1st. Dr. Austin brings more than 25 years of leadership across oncology discovery and early development and will play a key role In advancing VERAXA's BiTACTM platform and clinical-stage pipeline. "Dr. Austin's appointment comes at a transformative period for VERAXA and I'm looking forward to working with him as we enter the next phase in VERAXA's journey," commented Christoph Antz, Ph.D., CEO and Co-Founder of VERAXA

ZURICH, SWITZERLAND, May 5, 2025 -- VERAXA Biotech AG ("VERAXA"), an emerging leader in designing novel cancer therapies and proposed de-SPAC acquisition target of Voyager Acquisition Corp. (NASDAQ:VACH, "Voyager")), announced today a co-discovery alliance with OmniAb, Inc. (NASDAQ:OABI, "OmniAb")) for the development of a novel bispecific antibody drug conjugate ("bsADC") program targeting solid tumors. The collaboration brings together OmniAb's suite of transgenic antibody discovery solutions with VERAXA's proprietary antibody drug conjugate ("ADC") linker technology and conjugation expertise to support next-generation therapeutic discovery. "This partnership brings together two highly co

VERAXA's Novel BiTAC Platform has the Potential to Deliver Multiple Next-Generation Solid Tumor Cancer Therapies, Including Novel Antibody-Drug Conjugate ("ADC") and Bispecific T-cell Engager ("TCE") Candidates, with Strong and Differentiated Clinical ProfilesCompany Pursuing Multiple Strategic Partnerships and Licensing Opportunities in 2025 and 2026Transaction Values VERAXA at a Pre-money Equity Value of $1.3 BillionActively Working with Existing and New VERAXA Investors to Raise a Crossover Financing Round, which is Expected to Close Ahead of the Business Combination, Alongside up to $253 Million in Cash Held in TrustBusiness Combination is Expected to be Completed in the Fourth Quarter o

SC 13G - Voyager Acquisition Corp./Cayman Islands (0002006815) (Subject)

SC 13G - Voyager Acquisition Corp./Cayman Islands (0002006815) (Subject)

SC 13G/A - Voyager Acquisition Corp./Cayman Islands (0002006815) (Subject)

SC 13G - Voyager Acquisition Corp./Cayman Islands (0002006815) (Subject)

SC 13G/A - Voyager Acquisition Corp./Cayman Islands (0002006815) (Subject)